- Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. “The in-depth review of the clinical data to date reconfirms our confidence in BMF-219 as a novel, first-in-class agent for the treatment of diabetes,” stated Thomas Butler, Biomea Fusion’s CEO and Chairman. “We are encouraged from the safety
- Zacks
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
- Zacks
Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet
The consensus price target hints at a 317.9% upside potential for Biomea Fusion (BMEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
